PTC THERAPEUTICS, INC. (PTCT) Financials
Annual revenue, profitability and per-share results for PTC THERAPEUTICS, INC., as reported in SEC filings.
Revenue • FY2025
$1.73B
▲ 114.5%YoY
Net income • FY2025
$682.64M
▲ 287.9%YoY
Diluted EPS • FY2025
$7.78
▲ 264.5%YoY
Annual income statement
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $1.73B | $682.64M | — | $7.78 | $702.34M | 50.1% | +114.5% |
| FY2024 | $806.78M | -$363.3M | — | -$4.73 | -$114.19M | -37.5% | -14.0% |
| FY2023 | $937.82M | -$626.6M | — | -$8.37 | -$186.86M | -46.9% | +34.2% |
| FY2022 | $698.8M | -$559.02M | — | -$7.79 | -$388.67M | -64.0% | +29.8% |
Figures as reported in PTC THERAPEUTICS, INC.'s 10-K filings on SEC EDGAR. Fiscal years may differ from calendar years.
Never miss a PTCT filing.
Get an email when PTCT files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.